Findings from the phase III RANGE study indicate that adding ramucirumab to docetaxel may improve progression-free survival for patients with advanced or metastatic urothelial carcinoma whose disease is refractory to platinum chemotherapy.
from Cancer via ola Kala on Inoreader http://ift.tt/2iTuGGj
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου